Scienture Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCNX research report →
Range $6 – $6
Price Chart
About the company
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.
- CEO
- Shankar Hariharan
- IPO
- 2014
- Employees
- 9
- HQ
- Commack, NY, US
Get TickerSpark's AI analysis on SCNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.07M
- P/E
- -0.05
- Fwd P/E
- 2.48
- PEG
- 0.00
- P/S
- 2.74
- P/B
- 0.06
- EV/EBITDA
- -0.22
- Div Yield
- 0.00%
- Gross Margin
- 46.96%
- Op Margin
- -1015.39%
- Net Margin
- -2715.93%
- ROE
- -62.13%
- ROIC
- -18.16%
Latest fiscal year · YoY change
- Revenue
- $431.61K+215.9%
- Gross Profit
- $331.48K+5420.1%
- Op Income
- $-16,244,792
- Net Income
- $-41,512,264-557.9%
- EPS
- $-67.50-200.4%
- OCF Growth
- +6.2%
- FCF Growth
- +6.3%
- 52W High
- $18.75
- 52W Low
- $2.00
- 50D MA
- $4.34
- 200D MA
- $8.50
- Beta
- 4.31
- RSI (14)
- 24
- Avg Volume
- 156.51K
No earnings-call transcripts are available for SCNX yet.
- Free Float
- 71.6%
- Shares Outstanding
- 1.79M
- Float Shares
- 1.28M
of shares held by institutions
16 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 606.15K | ▲ 449.13K |
| Vanguard Capital Management LLC | 510.39K | 0 |
| Geode Capital Management, LLC | 334.97K | 0 |
| Susquehanna International Group, Llp | 235.12K | ▲ 235.12K |
| Vanguard Fiduciary Trust Co | 198.06K | 0 |
| Citadel Advisors LLC | 164.85K | ▲ 164.85K |
| Jane Street Group, LLC | 125.91K | ▲ 50.19K |
| Xtx Topco Ltd | 104.80K | ▲ 57.12K |
| Northern Trust Corp | 87.61K | ▲ 73.71K |
| Ubs Group AG | 67.73K | ▼ 18.19K |
| Virtu Financial LLC | 47.55K | ▼ 36.66K |
| Two Sigma Securities, LLC | 33.28K | ▼ 3.17K |
Held by 19 ETFs
Biggest fund positions in SCNX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 25 | Sherb Eric Michael | other | 50,000 |
| Dec 31, 25 | Sherb Eric Michael | other | 0 |
| Mar 13, 25 | Sherb Eric Michael | other | 0 |
| Feb 20, 26 | Shankar Hariharan | other | 500,000 |
| Oct 1, 25 | Shankar Hariharan | other | 300,000 |
| Apr 14, 25 | Shankar Hariharan | other | 750,000 |
| Sep 19, 24 | Shankar Hariharan | other | 1,916,816 |
| Mar 10, 25 | Shankar Hariharan | other | 30,000 |
| Sep 19, 24 | Shankar Hariharan | other | 356,480 |
| Sep 19, 24 | Shankar Hariharan | other | 356,480 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SCNX coverage
Recent articles, reports, and earnings notes.
No research on SCNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SCNX report →SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™
globenewswire.com · Nov 16
Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call Prepared Remarks Transcript
seekingalpha.com · Oct 28
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
globenewswire.com · Oct 22
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
globenewswire.com · Oct 13
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
globenewswire.com · Oct 2
Scienture Holdings, Inc. Announces Reverse Stock Split
globenewswire.com · Sep 30
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
globenewswire.com · Sep 22
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
globenewswire.com · Sep 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.